🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The study consists of two periods, the Screening Period (\~3 weeks) and Tre...
Status
Withdrawn
Location
Multiple Locations
Start Date
2015-06
Trial ID
NCT02435199
Treatments Being Tested
This is a safety, tolerability, pharmacokinetic and efficacy study in subje...
Status
Recruiting
Location
CHRU de Lille - Hôpital Roger Salengro
Start Date
2021-09-09
Trial ID
NCT04691661
Treatments Being Tested
The focus of this study is to test the safety and efficacy of the PCSK9 inh...
Status
Completed
Location
Stanford University
Start Date
2019-05-13
Trial ID
NCT03537742
Treatments Being Tested
This was a four month dose ranging study followed by a 24 to 48 month exten...
Status
Terminated
Location
Anasazi Internal Medicine
Start Date
2009-04
Trial ID
NCT00900146
Treatments Being Tested
This is a first-in-human,randomized, double-blind, placebo-controlled, sing...
Status
Completed
Location
Peking Union Medical College Hospital
Start Date
2018-05-23
Trial ID
NCT04169386
People with multiple sclerosis (MS) have nerve loss even without acute infl...
Status
Completed
Location
Barts Health NHS Trust
Start Date
2014-10
Trial ID
NCT02104661
Treatments Being Tested
This is a multicenter, randomized, double-blind, placebo-controlled phase I...
Status
Recruiting
Location
Fudan University Shanghai Cancer Center
Start Date
2026-03-27
Trial ID
NCT07300514
Treatments Being Tested
ARISTOCRAT is a phase II, multi-centre, double-blind, placebo-controlled, r...
Status
Recruiting
Location
Glan Clwyd Hospital
Start Date
2023-02-03
Trial ID
NCT05629702
Treatments Being Tested
This study is to assess the efficacy of bupropion in reducing methamphetami...
Status
Completed
Location
UCLA Integrated Substance Abuse Program
Start Date
2008-05
Trial ID
NCT00687713
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of...
Status
Completed
Location
London Lung Cancer Group
Start Date
2005-04
Trial ID
NCT00275132
Treatments Being Tested